Spotlighting innovation at the SCOPE Summit, finalists for the Site Innovation and Patient Engagement Awards showcase ...

Johnson & Johnson's $14.6bn acquisition of Intra-Cellular Therapies adds Caplyta and a robust pipeline targeting major ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

As India’s contract manufacturing and development organization (CDMO) is set to double in the next decade, Anthem Biosciences ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...

According to the terms of the deal, Gilead will select a set of drug targets and Terray will discover and develop small molecule drugs that bind to them. Gilead has the option to exclusively license ...

Palatin Technologies has announced topline results for the phase 2b Breakout study, which evaluated the effects of bremelanotide in patients with type 2 diabetic nephropathy. This condition is a ...